Texas Diabetes & Endocrinology, PA

Austin, Texas 78749

1 studies enrolling now · 32 studies all time

What they study most

Alzheimer Disease, Alzheimer's Disease, Cardiovascular Diseases, Chronic Kidney Disease, Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetes type1, Hypogonadism, Insulin Treated Type 2 Diabetes Mellitus, Obesity, Obesity or Overweight

Studies at this site

• A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes — Recruiting now
• A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease — Completed
• A Study Evaluating the Effect of Daily Oral RO7795081 in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity — Completed
• A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin — Running, not enrolling
• A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes — Running, not enrolling
• Innovative Automated Insulin Delivery System for Type 2 Diabetes — Completed
• A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1) — Completed
• A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity — Running, not enrolling
• A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight — Running, not enrolling
• A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk — Completed
• A Study of Enicepatide (CT-388) in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity — Completed
• A Study to Learn About the Study Medicine Called PF-07976016 in Adults With Obesity — Completed
• A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3) — Running, not enrolling
• A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity — Running, not enrolling
• A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities — Running, not enrolling
• A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight — Completed
• A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy — Completed
• A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections — Completed
• A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2) — Completed
• INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes — Completed
• A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight — Completed
• A Study of LY3437943 in Participants Who Have Obesity or Are Overweight — Completed
• A Study of Mealtime Insulin LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring (PRONTO-Time in Range) — Completed
• A Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Combination With Teplizumab in Participants With Recent-onset Diagnosed Type 1 Diabetes (T1D) — Completed
• A Phase 2 Study of LY3209590 in Participants With Type 2 Diabetes Mellitus — Completed
• A Study of LY3209590 in Participants With Type 1 Diabetes — Completed
• A Study to Evaluate Androderm®'s Effect on Blood Pressure in Adult Hypogonodal Male Participants — Completed
• A Study Comparing LY900014 to Insulin Lispro (Humalog) in Children and Adolescents With Type 1 Diabetes — Completed
• A Study of an Insulin Management System in Participants With Type 1 or Type 2 Diabetes — Completed
• Safety Study of Using Symlin Alongside Insulin in a Multiple Injection Port — Stopped early
• Comparison of Different Insulin Dosing Algorithms Using Hepatic Directed Vesicle-Insulin Lispro and Insulin Degludec — Completed
• Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3) — Completed